A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Tocilizumab (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Pharmacokinetics
- Acronyms MARIPOSA
- Sponsors Roche
Most Recent Events
- 09 Sep 2020 Status changed from active, no longer recruiting to completed.
- 23 Jul 2020 According to a Roche media release, results are expected later this year.
- 26 Jun 2020 Status changed from recruiting to active, no longer recruiting.